Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Abivax (AAVXF) Common Equity (2023 - 2025)

Historic Common Equity for Abivax (AAVXF) over the last 3 years, with Q3 2025 value amounting to $597.7 million.

  • Abivax's Common Equity changed N/A to $597.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $597.7 million, marking a year-over-year change of. This contributed to the annual value of $43.4 million for FY2024, which is 7954.61% down from last year.
  • Latest data reveals that Abivax reported Common Equity of $597.7 million as of Q3 2025.
  • Abivax's 5-year Common Equity high stood at $597.7 million for Q3 2025, and its period low was -$54.7 million during Q2 2025.
  • For the 3-year period, Abivax's Common Equity averaged around $154.4 million, with its median value being $89.8 million (2024).
  • Per our database at Business Quant, Abivax's Common Equity crashed by 7943.63% in 2024 and then plummeted by 14012.73% in 2025.
  • Quarter analysis of 3 years shows Abivax's Common Equity stood at $210.9 million in 2023, then crashed by 79.44% to $43.4 million in 2024, then surged by 1278.13% to $597.7 million in 2025.
  • Its Common Equity stands at $597.7 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$6.9 million for Q1 2025.